Characteristic | Derosa 2004 | Derosa 2006a | Derosa 2006b |
I1: rosiglitazone 4 mg + glimepiride 4 mg C1: pioglitazone 15 mg + glimepiride 4 mg | I1: rosiglitazone 4 mg + metformin 3000 mg C1: pioglitazone 15 mg + metformin 3000mg | I1: rosiglitazone 4 mg + metformin 1500 mg C1: glimepiride 2 mg+ metformin 1500 mg | |
Sex [%] | I1: female 48; male 52 C1: female 53; male 447 | I1: female 48; male 52 C1: female 50; male 50 | I1: female 48; male 52 C1: female 51; male 49 |
Age [years], mean (SD) | I1: 54 (5) C1: 53 (6) | I1: 56 (4) C1: 55 (5) | I1: 54 (4) C1: 52 (5) |
Ethnic groups [%] | I1: white 100 C1: white 100 | I1: caucasians 100 C1: caucasians 100 | ? |
Duration of disease [years], mean (SD) | I1: 6 (3) C1: 5 (2) | I1: 5(4) C1: 6(4) | I1: 5 (3) C1: 4 (3) |
Body mass index [kg/m2], mean (SD) | I1: 24.3 (0.7) C1: 24.4 (0.8) | I1: 26.4 (1.4) C1: 26.9 (1.2) | I1: 26.6 (1.3) C1: 26.8 (1.5) |
Pharmaco‐naive patients [%] | I1: none C1: none | I1: none C1: none | I1: none C1: none |
HbA1c [%], mean (SD) | I1: 8.0 (0.8) C1: 8.2 (0.7) | I1: 8.1 (0.9) C1: 8.2 (0.8) | I1: 8.0 (0.7) C1: 7.9 (0.6) |
Co‐morbidities [%] | ? | ? | I1: hypertension 42 C1: hypertension 47 |
Notes | patients who completed the study | ./. | ./. |
Footnotes ? = unclear; I = intervention; C = control; SD = standard deviation; SE = standard error; ITT = intention‐to ‐treat |